257 related articles for article (PubMed ID: 11435458)
1. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.
Ryu S; Kodama S; Ryu K; Schoenfeld DA; Faustman DL
J Clin Invest; 2001 Jul; 108(1):63-72. PubMed ID: 11435458
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.
Palmer JP
J Clin Invest; 2001 Jul; 108(1):31-3. PubMed ID: 11435453
[No Abstract] [Full Text] [Related]
3. Islet regeneration during the reversal of autoimmune diabetes in NOD mice.
Kodama S; Kühtreiber W; Fujimura S; Dale EA; Faustman DL
Science; 2003 Nov; 302(5648):1223-7. PubMed ID: 14615542
[TBL] [Abstract][Full Text] [Related]
4. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells.
Suri A; Calderon B; Esparza TJ; Frederick K; Bittner P; Unanue ER
Science; 2006 Mar; 311(5768):1778-80. PubMed ID: 16556846
[TBL] [Abstract][Full Text] [Related]
5. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration.
Chong AS; Shen J; Tao J; Yin D; Kuznetsov A; Hara M; Philipson LH
Science; 2006 Mar; 311(5768):1774-5. PubMed ID: 16556844
[TBL] [Abstract][Full Text] [Related]
6. Comment on papers by Chong et al., Nishio et al., and Suri et al. on diabetes reversal in NOD mice.
Faustman DL; Tran SD; Kodama S; Lodde BM; Szalayova I; Key S; Toth ZE; Mezey E
Science; 2006 Nov; 314(5803):1243; author reply 1243. PubMed ID: 17124308
[TBL] [Abstract][Full Text] [Related]
7. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution.
Nishio J; Gaglia JL; Turvey SE; Campbell C; Benoist C; Mathis D
Science; 2006 Mar; 311(5768):1775-8. PubMed ID: 16556845
[TBL] [Abstract][Full Text] [Related]
8. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy.
Wang T; Singh B; Warnock GL; Rajotte RV
Diabetes; 1992 Jan; 41(1):114-7. PubMed ID: 1727730
[TBL] [Abstract][Full Text] [Related]
9. Study on pancreatic lymphatics in nonobese diabetic mouse with prevention of insulitis and diabetes by adjuvant immunotherapy.
Qu P; Ji RC; Shimoda H; Miura M; Kato S
Anat Rec A Discov Mol Cell Evol Biol; 2004 Dec; 281(2):1326-36. PubMed ID: 15386276
[TBL] [Abstract][Full Text] [Related]
10. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells.
Grewal IS; Grewal KD; Wong FS; Picarella DE; Janeway CA; Flavell RA
J Exp Med; 1996 Nov; 184(5):1963-74. PubMed ID: 8920883
[TBL] [Abstract][Full Text] [Related]
11. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
[TBL] [Abstract][Full Text] [Related]
12. A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice.
Gurr W; Yavari R; Wen L; Shaw M; Mora C; Christa L; Sherwin RS
Diabetes; 2002 Feb; 51(2):339-46. PubMed ID: 11812740
[TBL] [Abstract][Full Text] [Related]
13. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha down-regulates type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice.
Rabinovitch A; Suarez-Pinzon WL; Sorensen O; Rajotte RV; Power RF
J Immunol; 1997 Dec; 159(12):6298-303. PubMed ID: 9550435
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes.
Bergot AS; Buckle I; Cikaluru S; Naranjo JL; Wright CM; Zheng G; Talekar M; Hamilton-Williams EE; Thomas R
J Immunol; 2020 Apr; 204(7):1787-1797. PubMed ID: 32111734
[TBL] [Abstract][Full Text] [Related]
16. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation.
Yang Z; Chen M; Ellett JD; Fialkow LB; Carter JD; Nadler JL
Transplantation; 2004 Jan; 77(1):55-60. PubMed ID: 14724435
[TBL] [Abstract][Full Text] [Related]
17. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade.
Makhlouf L; Kishimoto K; Smith RN; Abdi R; Koulmanda M; Winn HJ; Auchincloss H; Sayegh MH
Diabetes; 2002 Nov; 51(11):3202-10. PubMed ID: 12401711
[TBL] [Abstract][Full Text] [Related]
18. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
[TBL] [Abstract][Full Text] [Related]
19. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.
Pakala SV; Chivetta M; Kelly CB; Katz JD
J Exp Med; 1999 Apr; 189(7):1053-62. PubMed ID: 10190896
[TBL] [Abstract][Full Text] [Related]
20. Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients.
Prange S; Zucker P; Jevnikar AM; Singh B
Transplantation; 2001 Apr; 71(7):982-5. PubMed ID: 11349735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
